Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway

CLEARWATER, Fla., May 27, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), will return to Miami Swim Week with its Body by Apyx showcase, an immersive runway experience featuring real patient transformations.

PRNewsWire • May 27, 2026

New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®

Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach

GlobeNewsWire • May 21, 2026

Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction

CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open 1.

GlobeNewsWire • May 14, 2026

Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™

Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON

GlobeNewsWire • May 11, 2026

Apyx Medical Corporation (APYX) Q1 2026 Earnings Call Transcript

Apyx Medical Corporation (APYX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

Apyx Medical Corporation Reports First Quarter 2026 Financial Results

CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its first quarter ended March 31, 2026.

GlobeNewsWire • May 7, 2026

Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates

Apyx Medical (APYX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.1 per share a year ago.

Zacks Investment Research • May 7, 2026

Weight-loss revolution sparks new appetite for aesthetics firms

Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quarter earnings this week.

Reuters • May 4, 2026

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the first quarter of fiscal year 2026 will be released before markets open on Thursday, May 7th.

GlobeNewsWire • Apr 23, 2026

Renuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"

Renuvion continues to lead in minimally invasive body contouring as the trusted solution for loose skin. CLEARWATER, Fla.

PRNewsWire • Apr 1, 2026